πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12274723

Bacteriophage compositions and methods for treatment of bacterial infections

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12274747

Compositions and methods for treating cytokine release syndrome

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268693

Pharmaceutical compositions comprising a tolfenamic acid

AXSOME THERAPEUTICS, INC. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268694

Combination pharmaceutical agents as RSV inhibitors

Enanta Pharmaceuticals, Inc. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268720

Bacteriophage for treatment and prevention of E. coli and B. fragilis infections

Armata Pharmaceuticals, Inc. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12270814

Kits and methods for prediction and treatment of preeclampsia

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268730

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268737

Stabilized influenza hemagglutinin stem region trimers and uses thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268749

Cell-penetrating peptides

United Kingdom Research and Innovation Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12269887

Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same,

Regents of the University of Minnesota Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12269886

Tetravalent bispecific antibody against PD-1 and PD-L1

SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12269820

Piperazine substituted indazole compounds as inhibitors of PARG

IDEAYA Biosciences, Inc. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12269856

Hepcidin analogues and uses thereof

Protagonist Therapeutics, Inc. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12269808

Amino dithioperacid thioester compound, preparation method therefor, and use thereof

EAST CHINA NORMAL UNIVERSITY Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12269858

Activin receptor type IIB variants and methods of use thereof

Keros Therapeutics, Inc. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12269801

Modified amino acids

Sutro Biopharma, Inc. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12269803

KrΓΌppel-like factor 15 (KLF15) small molecule agonists in kidney disease

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12269860

Compositions and methods comprising engineered chimeric antigen receptor and modulator of

AUTOLUS LIMITED Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12269805

Inhibitors of platelet function and methods for use of the same

The Regents of the University of California Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12269831

Modulators of cystic fibrosis transmembrane conductance regulator

Vertex Pharmaceuticals Incorporated Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12269889

Human antibodies to the human glucagon receptor (HGCGR) and methods of use thereof to lowe

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12269872

Neutralizing antibodies to Plasmodium falciparum circumsporozoite protein and their use

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12269155

Multivalent vaccines for rabies virus and coronaviruses

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12268683

Compounds and methods for synergistic activation of M channels

The Regents of the University of California Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted